Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group
The purpose of this study was to report the 5-year outcomes of treatment-naive eyes with cystoid macular edema secondary to central retinal vein occlusion treated with intravitreal bevacizumab in routine clinical practice. We conducted multicenter retrospective non-comparative case series of 102 eye...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881509003378294784 |
|---|---|
| author | Lihteh Wu Dhariana Acón María H. Berrocal Roberto Gallego‐Pinazo Rosa Dolz‐Marco José A. Roca Maurício Maia Sergio Rojas Marcelo Zas J. Fernando Arévalo Jay Chhablani |
| author_browse | Dhariana Acón J. Fernando Arévalo Jay Chhablani José A. Roca Lihteh Wu Marcelo Zas María H. Berrocal Maurício Maia Roberto Gallego‐Pinazo Rosa Dolz‐Marco Sergio Rojas |
| author_facet | Lihteh Wu Dhariana Acón María H. Berrocal Roberto Gallego‐Pinazo Rosa Dolz‐Marco José A. Roca Maurício Maia Sergio Rojas Marcelo Zas J. Fernando Arévalo Jay Chhablani |
| author_sort | Lihteh Wu |
| collection | Producción científica |
| description | The purpose of this study was to report the 5-year outcomes of treatment-naive eyes with cystoid macular edema secondary to central retinal vein occlusion treated with intravitreal bevacizumab in routine clinical practice. We conducted multicenter retrospective non-comparative case series of 102 eyes. The main outcome measured was the change in best-corrected visual acuity (BCVA) at 5 years. Secondary outcomes included the number of injections and the change in CMT at 5 years. At 5 years, the mean BCVA improved from 1.22 ± 0.58 (Snellen 20/428) at baseline to 1.00 ± 0.68 logMAR (Snellen 20/200; p < 0.0001). At 5 years, 48 (47%) eyes had a gain of ≥ 3 lines, 41 (40.2%) eyes remained within 3 lines and 13 (12.7%) eyes had a loss of ≥ 3 lines of BCVA. The CMT improved from 740 ± 243 to 322 ± 179 µm (p < 0.0001). At 5 years, 59 (57.8%) eyes had a completely dry SD-OCT. Patients received a total of 10.6 ± 6.1 (range 6–27) injections. Baseline BCVA (p < 0.0001) and the duration of symptoms prior to initial anti-VEGF injection (p = 0.0274) were the only predictive factors for BCVA at 5 years. After 5 years with an average of 10.6 injections, there was a mean gain of 0.22 logMAR. In addition, more eyes achieved a BCVA of ≥ 20/40, gained ≥ 3 lines and less patients had a BCVA ≤ 20/200. Eyes with a better baseline BCVA and a shorter duration of symptoms were more likely to achieve better BCVA at 5 years. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/905 |
| institution | UPeU |
| language | English |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/9052026-11-02T22:34:06ZFive-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) groupLihteh WuDhariana AcónMaría H. BerrocalRoberto Gallego‐PinazoRosa Dolz‐MarcoJosé A. RocaMaurício MaiaSergio RojasMarcelo ZasJ. Fernando ArévaloJay ChhablaniMedicineMacular edemaOphthalmologyBevacizumabVisual acuityCentral retinal vein occlusionRetrospective cohort studySurgeryChemotherapyMedicineMacular edemaOphthalmologyBevacizumabVisual acuityCentral retinal vein occlusionRetrospective cohort studySurgeryChemotherapyBevacizumab therapeutic useBevacizumab therapeutic useBevacizumab therapeutic useHumansHumansHumansMacular Edema diagnosisMacular Edema diagnosisMacular Edema diagnosisMacular Edema drug therapyMacular Edema drug therapyMacular Edema drug therapyMacular Edema etiologyMacular Edema etiologyMacular Edema etiologyRetinaRetinaRetinaRetinal Vein Occlusion complicationsRetinal Vein Occlusion complicationsRetinal Vein Occlusion complicationsRetinal Vein Occlusion diagnosisRetinal Vein Occlusion diagnosisRetinal Vein Occlusion diagnosisRetinal Vein Occlusion drug therapyRetinal Vein Occlusion drug therapyRetinal Vein Occlusion drug therapyRetrospective StudiesRetrospective StudiesRetrospective StudiesTreatment OutcomeTreatment OutcomeTreatment OutcomeAngiogenesis InhibitorsAngiogenesis InhibitorsAngiogenesis InhibitorsTomography, Optical CoherenceTomography, Optical CoherenceTomography, Optical CoherenceVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AIntravitreal InjectionsIntravitreal InjectionsIntravitreal InjectionsHealth Sciences Medicine Ophthalmology Retinal Diseases and TreatmentsHealth Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s SyndromeHealth Sciences Medicine Radiology, Nuclear Medicine and Imaging Retinal and Macular SurgeryThe purpose of this study was to report the 5-year outcomes of treatment-naive eyes with cystoid macular edema secondary to central retinal vein occlusion treated with intravitreal bevacizumab in routine clinical practice. We conducted multicenter retrospective non-comparative case series of 102 eyes. The main outcome measured was the change in best-corrected visual acuity (BCVA) at 5 years. Secondary outcomes included the number of injections and the change in CMT at 5 years. At 5 years, the mean BCVA improved from 1.22 ± 0.58 (Snellen 20/428) at baseline to 1.00 ± 0.68 logMAR (Snellen 20/200; p < 0.0001). At 5 years, 48 (47%) eyes had a gain of ≥ 3 lines, 41 (40.2%) eyes remained within 3 lines and 13 (12.7%) eyes had a loss of ≥ 3 lines of BCVA. The CMT improved from 740 ± 243 to 322 ± 179 µm (p < 0.0001). At 5 years, 59 (57.8%) eyes had a completely dry SD-OCT. Patients received a total of 10.6 ± 6.1 (range 6–27) injections. Baseline BCVA (p < 0.0001) and the duration of symptoms prior to initial anti-VEGF injection (p = 0.0274) were the only predictive factors for BCVA at 5 years. After 5 years with an average of 10.6 injections, there was a mean gain of 0.22 logMAR. In addition, more eyes achieved a BCVA of ≥ 20/40, gained ≥ 3 lines and less patients had a BCVA ≤ 20/200. Eyes with a better baseline BCVA and a shorter duration of symptoms were more likely to achieve better BCVA at 5 years.Articlehttps://pubmed.ncbi.nlm.nih.gov/3462854410.1007/s10792-021-02077-5https://hdl.handle.net/20.500.15037/905W3206145898enInternational Ophthalmology0165-57011573-26302021-10-092026-06-13T09:40:06Z2026-06-13T09:40:06Z |
| spellingShingle | Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Bevacizumab therapeutic use Bevacizumab therapeutic use Bevacizumab therapeutic use Humans Humans Humans Macular Edema diagnosis Macular Edema diagnosis Macular Edema diagnosis Macular Edema drug therapy Macular Edema drug therapy Macular Edema drug therapy Macular Edema etiology Macular Edema etiology Macular Edema etiology Retina Retina Retina Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retrospective Studies Retrospective Studies Retrospective Studies Treatment Outcome Treatment Outcome Treatment Outcome Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Intravitreal Injections Intravitreal Injections Intravitreal Injections Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Retinal and Macular Surgery Lihteh Wu Dhariana Acón María H. Berrocal Roberto Gallego‐Pinazo Rosa Dolz‐Marco José A. Roca Maurício Maia Sergio Rojas Marcelo Zas J. Fernando Arévalo Jay Chhablani Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title | Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title_full | Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title_fullStr | Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title_full_unstemmed | Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title_short | Five-year outcomes after intravitreal bevacizumab of treatment-naive eyes with macular edema secondary to CRVO in routine clinical practice: Results of the Pan-American Collaborative Retina Study (PACORES) group |
| title_sort | five year outcomes after intravitreal bevacizumab of treatment naive eyes with macular edema secondary to crvo in routine clinical practice results of the pan american collaborative retina study pacores group |
| topic | Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Bevacizumab therapeutic use Bevacizumab therapeutic use Bevacizumab therapeutic use Humans Humans Humans Macular Edema diagnosis Macular Edema diagnosis Macular Edema diagnosis Macular Edema drug therapy Macular Edema drug therapy Macular Edema drug therapy Macular Edema etiology Macular Edema etiology Macular Edema etiology Retina Retina Retina Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retrospective Studies Retrospective Studies Retrospective Studies Treatment Outcome Treatment Outcome Treatment Outcome Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Intravitreal Injections Intravitreal Injections Intravitreal Injections Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Retinal and Macular Surgery |
| topic_facet | Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Medicine Macular edema Ophthalmology Bevacizumab Visual acuity Central retinal vein occlusion Retrospective cohort study Surgery Chemotherapy Bevacizumab therapeutic use Bevacizumab therapeutic use Bevacizumab therapeutic use Humans Humans Humans Macular Edema diagnosis Macular Edema diagnosis Macular Edema diagnosis Macular Edema drug therapy Macular Edema drug therapy Macular Edema drug therapy Macular Edema etiology Macular Edema etiology Macular Edema etiology Retina Retina Retina Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion complications Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion diagnosis Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retinal Vein Occlusion drug therapy Retrospective Studies Retrospective Studies Retrospective Studies Treatment Outcome Treatment Outcome Treatment Outcome Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Tomography, Optical Coherence Tomography, Optical Coherence Tomography, Optical Coherence Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Intravitreal Injections Intravitreal Injections Intravitreal Injections Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Retinal and Macular Surgery |
| url | https://pubmed.ncbi.nlm.nih.gov/34628544 https://hdl.handle.net/20.500.15037/905 |
| work_keys_str_mv | AT lihtehwu fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT dharianaacon fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT mariahberrocal fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT robertogallegopinazo fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT rosadolzmarco fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT josearoca fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT mauriciomaia fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT sergiorojas fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT marcelozas fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT jfernandoarevalo fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup AT jaychhablani fiveyearoutcomesafterintravitrealbevacizumaboftreatmentnaiveeyeswithmacularedemasecondarytocrvoinroutineclinicalpracticeresultsofthepanamericancollaborativeretinastudypacoresgroup |